What UK opposition leader Jeremy Corbyn's policy proposals could mean for pharma

David Baker, a business consultant at  J+D Forecasting, provides an Expert View on potential implications for the pharmaceutical industry of UK Labour Party leader Jeremy Corbyn's recently-announced proposals.

The pharmaceutical sector is one of the most productive in the UK, with a turnover of £41.8 billion ($54 billion), providing 8.2% of UK goods exports and employing more than 113,000 people, directly or in service and supply roles.

The sector is a mixture of large UK-headquartered firms such as AstraZeneca (LSE: AZN) and GlaxoSmithKline (LSE: GSK), manufacturing and research sites for other global companies, and a significant proportion of small and medium-sized enterprises (SMEs) and microbusinesses, researching and manufacturing branded, generic and over-the-counter medicines for UK patients and consumers and for a global market(1).